Lycia Therapeutics, Inc.

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that remove disease-driving proteins from outside cells. Its core technology, the lysosomal targeting chimera platform, is designed to direct soluble and membrane-bound extracellular proteins to lysosomes, the cell’s natural waste-processing compartments, for degradation. This approach supports the development of targeted protein degraders for conditions in oncology, immunology, inflammation, and other areas of significant unmet medical need. The company’s current pipeline includes cataLYTAC programs such as LCA-0061, focused on allergic disease, and LCA-0321, directed toward Graves’ disease. By addressing proteins that may be difficult to inhibit with conventional drug modalities, Lycia Therapeutics, Inc. operates at the intersection of protein biology, drug discovery, and precision medicine. Headquartered in South San Francisco, California, the company represents a specialized biotechnology business focused on translating extracellular protein degradation into potential therapeutic products.

Company profile (no 10-K business section on file)